Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $32.31 in the prior trading day, Avidity Biosciences Inc (NASDAQ: RNA) closed at $32.00, down -0.96%. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 0.92 million shares were traded.
Ratios:
Our goal is to gain a better understanding of RNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.76 and its Current Ratio is at 17.76. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 20, 2024, initiated with a Buy rating and assigned the stock a target price of $72.
On November 26, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $67.
On September 24, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $59.Goldman initiated its Buy rating on September 24, 2024, with a $59 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 03 ’25 when Gallagher Kathleen P. sold 5,875 shares for $32.16 per share. The transaction valued at 188,918 led to the insider holds 50,554 shares of the business.
KATHLEEN GALLAGHER bought 17,625 shares of RNA for $580,391 on Feb 03 ’25. On Jan 21 ’25, another insider, LEVIN ARTHUR A, who serves as the Director of the company, sold 1,872 shares for $28.60 each. As a result, the insider received 53,537 and left with 12,958 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 377.26 while its Price-to-Book (P/B) ratio in mrq is 2.53.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $13.21. The 50-Day Moving Average of the stock is -0.12%, while the 200-Day Moving Average is calculated to be -16.76%.
Shares Statistics:
A total of 118.90M shares are outstanding, with a floating share count of 106.75M. Insiders hold about 10.53% of the company’s shares, while institutions hold 104.57% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 9.0 analysts. The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.62 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.58 and -$3.06 for the fiscal current year, implying an average EPS of -$2.86. EPS for the following year is -$3.16, with 10.0 analysts recommending between -$2.48 and -$4.54.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $12.8M, while the lowest revenue estimate was $7.9M, resulting in an average revenue estimate of $9.75M. In the same quarter a year ago, actual revenue was $9.56M
